These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 12015687)
1. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Wood GC; Hanes SD; Croce MA; Fabian TC; Boucher BA Clin Infect Dis; 2002 Jun; 34(11):1425-30. PubMed ID: 12015687 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Betrosian AP; Frantzeskaki F; Xanthaki A; Douzinas EE J Infect; 2008 Jun; 56(6):432-6. PubMed ID: 18501431 [TBL] [Abstract][Full Text] [Related]
3. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Jellison TK; Mckinnon PS; Rybak MJ Pharmacotherapy; 2001 Feb; 21(2):142-8. PubMed ID: 11213849 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests. Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302 [TBL] [Abstract][Full Text] [Related]
5. A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii. Ackerman BH; Haith LR; Patton ML; Guilday RE; Reigart CL; Stair-Buchmann M J Burn Care Res; 2013; 34(4):403-12. PubMed ID: 23237825 [TBL] [Abstract][Full Text] [Related]
6. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Shorr AF; Zadeikis N; Jackson WL; Ramage AS; Wu SC; Tennenberg AM; Kollef MH Clin Infect Dis; 2005 Feb; 40 Suppl 2():S123-9. PubMed ID: 15712100 [TBL] [Abstract][Full Text] [Related]
7. Utility of ampicillin-sulbactam for empiric treatment of ventilator-associated pneumonia in a trauma population. McMillian WD; Bednarik JL; Aloi JJ; Ahern JW; Crookes BA J Trauma; 2010 Oct; 69(4):861-5. PubMed ID: 20938272 [TBL] [Abstract][Full Text] [Related]
8. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Lee NY; Wang CL; Chuang YC; Yu WL; Lee HC; Chang CM; Wang LR; Ko WC Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460 [TBL] [Abstract][Full Text] [Related]
9. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Garnacho-Montero J; Ortiz-Leyba C; Jiménez-Jiménez FJ; Barrero-Almodóvar AE; García-Garmendia JL; Bernabeu-WittelI M; Gallego-Lara SL; Madrazo-Osuna J Clin Infect Dis; 2003 May; 36(9):1111-8. PubMed ID: 12715304 [TBL] [Abstract][Full Text] [Related]
10. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. Yanagihara K; Fukuda Y; Seki M; Izumikawa K; Higashiyama Y; Miyazaki Y; Hirakata Y; Tomono K; Mizuta Y; Tsukamoto K; Kohno S Intern Med; 2006; 45(17):995-9. PubMed ID: 17015999 [TBL] [Abstract][Full Text] [Related]
11. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS J Antimicrob Chemother; 2008 Jun; 61(6):1369-75. PubMed ID: 18367459 [TBL] [Abstract][Full Text] [Related]
12. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. Pachón-Ibáñez ME; Fernández-Cuenca F; Docobo-Pérez F; Pachón J; Pascual A J Antimicrob Chemother; 2006 Sep; 58(3):689-92. PubMed ID: 16870647 [TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia. Choi JY; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YK; Kim MS; Kim YA; Song YG; Yong D; Lee K; Kim JM Yonsei Med J; 2006 Feb; 47(1):63-9. PubMed ID: 16502486 [TBL] [Abstract][Full Text] [Related]
15. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H; Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586 [TBL] [Abstract][Full Text] [Related]
16. [Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study]. Rodloff AC; Laubenthal HJ; Bastian A; Bestehorn K; Büchele G; Gaus W Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Apr; 31(3):172-80. PubMed ID: 8672620 [TBL] [Abstract][Full Text] [Related]
17. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862 [TBL] [Abstract][Full Text] [Related]
18. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients. Kuo BI; Fung CP; Liu CY Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445 [TBL] [Abstract][Full Text] [Related]
19. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Michalopoulos A; Fotakis D; Virtzili S; Vletsas C; Raftopoulou S; Mastora Z; Falagas ME Respir Med; 2008 Mar; 102(3):407-12. PubMed ID: 18060758 [TBL] [Abstract][Full Text] [Related]